The Integrated Forecasting and Analysis Tool   Login Now

Alnylam Pharmaceuticals

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Alnylam Pharmaceuticals are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Alnylam Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Alnylam Pharmaceuticals - ALN-RSV01 Systemic Anti-infectives Anti-virals RSV RNAi therapeutic Phase II   - PD Central Nervous System Anti-Parkinson's agents Alpha-synuclein RNAi therapeutic Pre-clinical   - SCI Central Nervous System Other CNS drugs Nogo RNAi therapeutic Research project

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Alnylam Pharmaceuticals   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 1,076 1,076        PE Ratio (diluted) - Normalised (x) (13.3) (24.8)        Valuing the Enterprise        Enterprise Value 627 627        Free Cash Flow (Pre-Dividends) (18) (29)        FCF Yield (%) (2.8%) (4.6%)    Forecast Financials   Income Statement      Total Revenues 6 27      S,G & A (14) (17)      R&D (35) (49)      Other Income/ Expense - Net 0 0      EBIT - Normalised (43) (40)      Net Interest & Financial Items 1 5      Pre-tax Profits - Normalised (43) (35)      Income Before Taxes (43) (35)      Tax 0 0      Tax Rate (%) 0.0% 0.0%      Other After Tax Items (1) 1      Net Income - Reported (43) (34)      Net Income - Normalised (43) (34)     Per Share Data      EPS - Diluted (1.98) (1.06)      EPS - Basic (1.98) (1.06)      EPS - Normalised (diluted) (1.98) (1.06)      EPS - Normalised (basic) (1.98) (1.06)      Avg. Shares Outstanding - Diluted 21.9 31.9      Avg. Shares Outstanding - Basic 21.9 31.9      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Alnylam and Collaborators Publish In Vivo Research on Validation of a Mammalian Host Gene Involved in Malaria Infection and on the Anti-Parasitic Efficacy of RNAi Therapeutics   (Alnylam Pharmaceuticals)   21-May-2008 Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection   (Alnylam Pharmaceuticals)   09-Apr-2008 Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML) Programs at RNAi Keystone Symposium   (Alnylam Pharmaceuticals)   31-Mar-2008 Alnylam Achieves First Human Proof of Concept for an RNAi Therapeutic with GEMINI Study   (Alnylam Pharmaceuticals)   29-Feb-2008 Alnylam Reports Pre-clinical Progress with RNAi Therapeutics in Neurological Disease   (Alnylam Pharmaceuticals)   07-Feb-2008 Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection   (Alnylam Pharmaceuticals)   23-Jan-2008 Alnylam Launches its RNAi 2010 Outlook for Key Scientific, Clinical, and Business Initiatives; Announces Goals and Guidance for 2008   (Alnylam Pharmaceuticals)   07-Jan-2008 Alnylam Reports Continued Progress in Clinical Development of ALN-RSV01 for the Treatment of Respiratory Syncytial Virus (RSV) Infection   (Alnylam Pharmaceuticals)   13-Dec-2007 Regulus Therapeutics and Collaborators Announce Publication of New Research on the Role of microRNAs in Regulating Pathways of Viral Infection   (Regulus Therapeutics)   25-Oct-2007 Alnylam and Collaborators Publish New Pre-clinical Results on RNAi Therapeutics for the Treatment of Huntington's Disease   (Alnylam Pharmaceuticals)   17-Oct-2007 Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels   (Alnylam Pharmaceuticals)   08-Oct-2007 Alnylam and Collaborators Publish New Research on the In Vivo Mechanisms for Systemic Delivery of RNAi Therapeutics   (Alnylam Pharmaceuticals)   17-Sep-2007 Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases   (Alnylam Pharmaceuticals)   30-Jul-2007 Alnylam Announces Achievement of Key Milestone in Collaboration Agreement   (Isis Pharmaceuticals)   27-Jun-2007 Alnylam Announces Achievement of Key Milestone in Collaboration Agreement   (Alnylam Pharmaceuticals)   27-Jun-2007 Alnylam Initiates Phase II Clinical Trial to Evaluate Safety and Anti-viral Efficacy of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus (RSV) Infection   (Alnylam Pharmaceuticals)   26-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Alnylam Pharmaceuticals ALN-FLU01 -   ALN-HTT -   ALN-PCS01 -   ALN-RSV01 -   ALN-VEG01 -   ALN-VSP01 -   Alnylam/Roche RNAi collaboration -   Calando Cancer RNAi Therapeutic -   CF -   Dystonia RNAi Therapeutic -   Genecare Cancer RNAi Therapeutic -   Inflammatory microRNA Research Project -   IPF RNAi Therapeutic -   miR-122 antagonist -   miR-181 antagonist -   Neuropathic Pain Program -   Obesity RNAi therapeutic -   Ocular RNAi Therapeutic -   Oncology Research Program -   PD -   PFTi -   PML RNAi Therapeutic -   Respiratory RNAi Therapeutic -   RTP801i -   SCI -   TNF Alpha RNAi Therapeutic -   Viral Disease RNAi Therapeutic -   Viral Hemorrhagic Fever RNAi Therapeutic -

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:53:45 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd